Brief

On July 18, 2025, the Medicines and Healthcare products Regulatory Agency (MHRA) issued an update regarding "MHRA approves adrenaline nasal spray - the first needle-free emergency treatment for anaphylaxis in the UK". The MHRA approved adrenaline nasal spray (EURneffy), a ready-to-use single dose nasal spray, to treat serious allergic reactions. This approval provides a new option for emergency treatment of anaphylaxis, which is a sudden and potentially life-threatening condition.

This content is restricted.

Highlights content goes here...

This content is restricted.

Medicines and Healthcare products Regulatory Agency (MHRA)

Quick Insight
RADA.AI
RADA.AI
Hello! I'm RADA.AI - Regulatory Analysis and Decision Assistance. Your Intelligent guide for compliance and decision-making. How can i assist you today?
Suggested

Form successfully submitted. One of our GRI rep will contact you shortly

Thanking You!

Enter your Email

Enter your registered username/email id.

Enter your Email

Enter your email id below to signup.
Individual Plan
$125 / month OR $1250 / year
Features
Best for: Researchers, Legal professionals, Academics
Enterprise Plan
Contact for Pricing
Features
Best for: Law Firms, Corporations, Government Bodies